ATOS (Atossa Therapeutics, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by ATOS officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-05-14 | H. Lawrence Remmel | Director | A | — | — |
| 2026-05-14 | Jonathan Finn | Director | A | — | — |
| 2026-05-14 | Richard I Steinhart | Director | A | — | — |
| 2026-05-14 | Stephen J Galli | Director | A | — | — |
| 2026-05-14 | Shu-Chih Chen | Director | A | — | — |
| 2026-05-14 | Tessa Cigler | Director | A | — | — |
| 2026-03-30 | Mark James Daniel | Chief Financial Officer | A | — | — |
| 2026-01-30 | STEVEN C QUAY | President & CEO | A | — | — |
| 2026-01-22 | STEVEN C QUAY | President & CEO | A | — | — |
| 2025-10-21 | Mark James Daniel | Chief Financial Officer | A | — | — |
| 2025-05-22 | STEVEN C QUAY | President & CEO | Buy | — | — |
| 2025-05-16 | Tessa Cigler | Director | A | — | — |
| 2025-05-16 | Stephen J Galli | Director | A | — | — |
| 2025-05-16 | Richard I Steinhart | Director | A | — | — |
| 2025-05-16 | Shu-Chih Chen | Director | A | — | — |
| 2025-05-16 | STEVEN C QUAY | President & CEO | A | — | — |
| 2025-05-16 | Heather Rees | Chief Financial Officer | A | — | — |
| 2025-05-16 | Jonathan Finn | Director | A | — | — |
| 2025-05-16 | H. Lawrence Remmel | Director | A | — | — |
| 2025-03-28 | H. Lawrence Remmel | Director | Buy | — | — |
| 2024-07-01 | Jonathan Finn | Director | A | — | — |
| 2024-07-01 | H. Lawrence Remmel | Director | A | — | — |
| 2024-07-01 | Heather Rees | SVP, Finance and Accounting | A | — | — |
| 2024-07-01 | Tessa Cigler | Director | A | — | — |
| 2024-07-01 | Richard I Steinhart | Director | A | — | — |
| 2024-07-01 | Stephen J Galli | Director | A | — | — |
| 2024-07-01 | Shu-Chih Chen | Director | A | — | — |
| 2024-07-01 | STEVEN C QUAY | President & CEO | A | — | — |
| 2024-04-11 | Jonathan Finn | Director | Buy | — | — |
| 2024-03-14 | Tessa Cigler | Director | A | — | — |
| 2023-11-17 | GREGORY L WEAVER | Former EVP, CFO, & Director | Sell | — | — |
| 2023-11-15 | Jonathan Finn | Director | A | — | — |
| 2023-11-15 | Jonathan Finn | Director | A | — | — |
| 2023-06-20 | GREGORY L WEAVER | EVP & CFO | Buy | — | — |
| 2023-06-05 | GREGORY L WEAVER | EVP & CFO | A | — | — |
| 2023-05-05 | H. Lawrence Remmel | Director | A | — | — |
| 2023-05-05 | Shu-Chih Chen | Director | A | — | — |
| 2023-05-05 | Stephen J Galli | Director | A | — | — |
| 2023-05-05 | GREGORY L WEAVER | Director | A | — | — |
| 2023-05-05 | Richard I Steinhart | Director | A | — | — |
| 2023-03-06 | STEVEN C QUAY | President & CEO | A | — | — |
| 2023-03-06 | Kyle Guse | CFO, Gen Counsel and Secretary | A | — | — |
| 2022-05-16 | Richard I Steinhart | Director | A | — | — |
| 2022-05-16 | Stephen J Galli | Director | A | — | — |
| 2022-05-16 | GREGORY L WEAVER | Director | A | — | — |
| 2022-05-16 | Shu-Chih Chen | Director | A | — | — |
| 2022-05-16 | H. Lawrence Remmel | Director | A | — | — |
| 2022-02-28 | STEVEN C QUAY | President & CEO | A | — | — |
| 2022-02-28 | Kyle Guse | CFO, Gen Counsel and Secretary | A | — | — |
| 2021-07-07 | GREGORY L WEAVER | Director | MIXED | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Chief Financial Officer | 63,000 | — |
| — | President & CEO | 24,522 | — |
| — | Director | 11,666 | — |
| — | Director | 11,483 | — |
| — | Director | 10,684 | — |
| — | Director | 10,006 | — |
| — | Director | 10,000 | — |
| — | Director | 10,000 | — |
| — | CFO, Gen Counsel and Secretary | 48 | — |
| — | Director | 33 | — |
| — | Former EVP, CFO, & Director | 4 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ATOS quote page; the site-wide leaderboard is on the insider transactions hub.